2I1m image
Deposition Date 2006-08-14
Release Date 2006-11-28
Last Version Date 2024-02-21
Entry Detail
PDB ID:
2I1M
Keywords:
Title:
cFMS tyrosine kinase (tie2 KID) in complex with an arylamide inhibitor
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.80 Å
R-Value Free:
0.28
R-Value Work:
0.23
R-Value Observed:
0.25
Space Group:
H 3
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Macrophage colony-stimulating factor 1 receptor
Gene (Uniprot):CSF1R
Chain IDs:A
Chain Length:333
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.
J.Biol.Chem. 282 4094 4101 (2007)
PMID: 17132624 DOI: 10.1074/jbc.M608183200

Abstact

The cFMS proto-oncogene encodes for the colony-stimulating factor-1 receptor, a receptor-tyrosine kinase responsible for the differentiation and maturation of certain macrophages. Upon binding its ligand colony-stimulating factor-1 cFMS autophosphorylates, dimerizes, and induces phosphorylation of downstream targets. We report the novel crystal structure of unphosphorylated cFMS in complex with two members of different classes of drug-like protein kinase inhibitors. cFMS exhibits a typical bi-lobal kinase fold, and its activation loop and DFG motif are found to be in the canonical inactive conformation. Both ATP competitive inhibitors are bound in the active site and demonstrate a binding mode similar to that of STI-571 bound to cABL. The DFG motif is prevented from switching into the catalytically competent conformation through interactions with the inhibitors. Activation of cFMS is also inhibited by the juxtamembrane domain, which interacts with residues of the active site and prevents formation of the activated kinase. Together the structures of cFMS provide further insight into the autoinhibition of receptor-tyrosine kinases via their respective juxtamembrane domains; additionally the binding mode of two novel classes of kinase inhibitors will guide the design of novel molecules targeting macrophage-related diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures